Kardigan reported mixed Phase 2 results for tonlamarsen (licensed from Ionis Pharmaceuticals) in uncontrolled hypertension: the antisense oligonucleotide reduced angiotensinogen (AGT) by Week 20, but missed the co-primary blood pressure endpoint. The company said the single-dose arm’s unexpected, prolonged blood pressure drop blurred separation from the multi-dose group, while both arms showed clinically meaningful reductions versus baseline.